Evoke Pharma (EVOK) Sets New 12-Month Low at $2.17

Evoke Pharma Inc (NASDAQ:EVOK) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $2.17 and last traded at $2.43, with a volume of 53200 shares traded. The stock had previously closed at $2.43.

Several equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Evoke Pharma in a research report on Tuesday, October 24th. Zacks Investment Research upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Monday, November 20th. B. Riley restated a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a research note on Wednesday, November 15th. Northland Securities restated a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a research note on Wednesday, October 18th. Finally, FBR & Co restated a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a research note on Thursday, October 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $9.14.

The company has a market cap of $37.61, a P/E ratio of -2.22 and a beta of 1.26.

Several hedge funds have recently made changes to their positions in EVOK. Creative Planning purchased a new position in shares of Evoke Pharma in the fourth quarter valued at $226,000. B. Riley Financial Inc. purchased a new position in shares of Evoke Pharma in the fourth quarter valued at $249,000. Deutsche Bank AG purchased a new position in shares of Evoke Pharma in the fourth quarter valued at $452,000. Vanguard Group Inc. boosted its stake in shares of Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after purchasing an additional 68,544 shares during the period. Finally, Sphera Funds Management LTD. boosted its stake in shares of Evoke Pharma by 34.7% in the fourth quarter. Sphera Funds Management LTD. now owns 769,149 shares of the specialty pharmaceutical company’s stock valued at $1,738,000 after purchasing an additional 198,127 shares during the period. Institutional investors and hedge funds own 14.29% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.themarketsdaily.com/2018/02/15/evoke-pharma-evok-sets-new-12-month-low-at-2-17.html.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply